347 related articles for article (PubMed ID: 25256602)
1. Interactions between calcium and alpha-synuclein in neurodegeneration.
Rcom-H'cheo-Gauthier A; Goodwin J; Pountney DL
Biomolecules; 2014 Aug; 4(3):795-811. PubMed ID: 25256602
[TBL] [Abstract][Full Text] [Related]
2. Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies.
Rcom-H'cheo-Gauthier AN; Osborne SL; Meedeniya AC; Pountney DL
Front Neurosci; 2016; 10():570. PubMed ID: 28066161
[TBL] [Abstract][Full Text] [Related]
3. Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation.
Goodwin J; Nath S; Engelborghs Y; Pountney DL
Neurochem Int; 2013 Apr; 62(5):703-11. PubMed ID: 23159813
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model.
Rcom-H'cheo-Gauthier AN; Davis A; Meedeniya ACB; Pountney DL
Mol Cell Neurosci; 2016 Dec; 77():65-75. PubMed ID: 27746320
[TBL] [Abstract][Full Text] [Related]
5. Calcipotriol inhibits α-synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism.
Rcom-H'cheo-Gauthier AN; Meedeniya AC; Pountney DL
J Neurochem; 2017 Apr; 141(2):263-274. PubMed ID: 28164279
[TBL] [Abstract][Full Text] [Related]
6. Potassium depolarization and raised calcium induces α-synuclein aggregates.
Follett J; Darlow B; Wong MB; Goodwin J; Pountney DL
Neurotox Res; 2013 May; 23(4):378-92. PubMed ID: 23250862
[TBL] [Abstract][Full Text] [Related]
7. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.
Ottolini D; Calí T; Szabò I; Brini M
Biol Chem; 2017 Jan; 398(1):77-100. PubMed ID: 27508962
[TBL] [Abstract][Full Text] [Related]
9. High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease.
Macchi F; Deleersnijder A; Van den Haute C; Munck S; Pottel H; Michiels A; Debyser Z; Gerard M; Baekelandt V
J Neurosci Methods; 2016 Mar; 261():117-27. PubMed ID: 26620202
[TBL] [Abstract][Full Text] [Related]
10. Switching on Endogenous Metal Binding Proteins in Parkinson's Disease.
McLeary FA; Rcom-H'cheo-Gauthier AN; Goulding M; Radford RAW; Okita Y; Faller P; Chung RS; Pountney DL
Cells; 2019 Feb; 8(2):. PubMed ID: 30791479
[TBL] [Abstract][Full Text] [Related]
11. Beyond neurodegenerative diseases: α-synuclein in erythropoiesis.
Ling L; Wang F; Yu D
Hematology; 2022 Dec; 27(1):629-635. PubMed ID: 35621991
[TBL] [Abstract][Full Text] [Related]
12. Implementing Complementary Approaches to Shape the Mechanism of α-Synuclein Oligomerization as a Model of Amyloid Aggregation.
Giampà M; Amundarain MJ; Herrera MG; Tonali N; Dodero VI
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011320
[TBL] [Abstract][Full Text] [Related]
13. Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.
Grassi D; Diaz-Perez N; Volpicelli-Daley LA; Lasmézas CI
Neurobiol Dis; 2019 Apr; 124():248-262. PubMed ID: 30472299
[TBL] [Abstract][Full Text] [Related]
14. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
16. Molecular chaperones, α-synuclein, and neurodegeneration.
Witt SN
Mol Neurobiol; 2013 Apr; 47(2):552-60. PubMed ID: 22923346
[TBL] [Abstract][Full Text] [Related]
17. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Collier TJ; Srivastava KR; Justman C; Grammatopoulous T; Hutter-Paier B; Prokesch M; Havas D; Rochet JC; Liu F; Jock K; de Oliveira P; Stirtz GL; Dettmer U; Sortwell CE; Feany MB; Lansbury P; Lapidus L; Paumier KL
Neurobiol Dis; 2017 Oct; 106():191-204. PubMed ID: 28711409
[TBL] [Abstract][Full Text] [Related]
18. The many faces of α-synuclein: from structure and toxicity to therapeutic target.
Lashuel HA; Overk CR; Oueslati A; Masliah E
Nat Rev Neurosci; 2013 Jan; 14(1):38-48. PubMed ID: 23254192
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
20. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.
Xu MM; Ryan P; Rudrawar S; Quinn RJ; Zhang HY; Mellick GD
Acta Pharmacol Sin; 2020 Apr; 41(4):483-498. PubMed ID: 31586134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
